{"id":61015,"date":"2024-02-28T07:20:47","date_gmt":"2024-02-28T07:20:47","guid":{"rendered":"https:\/\/medsname.com\/udiliv\/"},"modified":"2026-04-30T10:23:39","modified_gmt":"2026-04-30T10:23:39","slug":"udiliv","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/udiliv\/","title":{"rendered":"Udiliv"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:0 0 18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Gyors v\u00e1lasz<\/h3>\n<p><strong>Udiliv<\/strong> tartalmaz <strong>ursodeoxycholsav (UDCA) 300 mg<\/strong> tablett\u00e1nk\u00e9nt \u2013 az er\u0151sebb hat\u00f3anyagtartalm\u00fa UDCA els\u0151dleges epe\u00fati cholangitis (PBC), cholesterol epek\u0151 felold\u00e1s, terhess\u00e9gi intrahepatic cholestasis \u00e9s egy\u00e9b cholestatic m\u00e1jbetegs\u00e9gek kezel\u00e9s\u00e9re. A 300 mg-os er\u0151ss\u00e9g fel\u00e9re cs\u00f6kkenti a napi tablettabev\u00e9telt a 150 mg-os form\u00e1hoz (Ursodec) k\u00e9pest.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f6f8;border:1px solid #e1e4e8;border-radius:4px;padding:14px 18px;margin:18px 0;display:flex;flex-wrap:wrap;gap:14px;font-size:0.95em;\"><span>\u2705 <strong>WHO-GMP tan\u00fas\u00edtv\u00e1nnyal rendelkezik<\/strong> gy\u00e1rt\u00f3<\/span><span>\ud83d\udce6 <strong>Diszkr\u00e9t csomagol\u00e1s<\/strong><\/span><span>\ud83c\udf0d <strong>Sz\u00e1ll\u00edt\u00e1s vil\u00e1gszerte<\/strong><\/span><span>\ud83d\udcac <a href=\"\/hu\/reviews\/\">1,400+ v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a><\/span><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Minden rendel\u00e9st fedez a <a href=\"https:\/\/medsbase.com\/hu\/medsbase-re-shipment-assurance-policy\/\"><strong>\u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n<h2>Mi az ursodeoxycholic acid<\/h2>\n<p>Az ursodeoxycholic acid (UDCA, m\u00e1s n\u00e9ven ursodiol) term\u00e9szetes m\u00e1sodlagos epesav. Ter\u00e1pi\u00e1s szempontb\u00f3l h\u00e1rom dolgot v\u00e9gez egyszerre: <strong>kiszor\u00edtja a citotoxikus hidrof\u00f3b epesavakat<\/strong> (chenodeoxycholic, deoxycholic, lithocholic) az epesav-k\u00e9szletb\u0151l, <strong>cs\u00f6kkenti a biliaryis koleszterin termel\u0151d\u00e9st<\/strong> (ami h\u00f3napok alatt feloldja a koleszterin epek\u0151ket), \u00e9s <strong>v\u00e9di a cholangiocyte-okat<\/strong> az epesav \u00e1ltal okozott k\u00e1rosod\u00e1st\u00f3l citoprotekt\u00edv \u00e9s immunmodul\u00e1tor hat\u00e1sokon kereszt\u00fcl. Ez az egyetlen or\u00e1lis ter\u00e1pia, amely mortalit\u00e1si \u00e9s transzplant\u00e1ci\u00f3mentes t\u00fal\u00e9l\u00e9si el\u0151nnyel j\u00e1r az els\u0151dleges epe\u00fati cholangitisben (Poupon 1991, 1994; meta-anal\u00edzisek 2002, 2014).<\/p>\n<h2>Indik\u00e1ci\u00f3k<\/h2>\n<ul>\n<li><strong>Prim\u00e9r biliaris cholangitis (PBC)<\/strong> \u2014 els\u0151 vonalbeli ter\u00e1pia; 13\u201315 mg\/nap\/kg \u00e9tkez\u00e9ssel egy\u00fctt osztott adagokban. ~60\u201370% biok\u00e9miai v\u00e1lasz (alk\u00e1los foszfat\u00e1z normaliz\u00e1ci\u00f3 vagy jelent\u0151s cs\u00f6kken\u00e9s) 12 h\u00f3nap alatt. A nem v\u00e1laszol\u00f3kat obeticholic acidra vagy fibr\u00e1tokra cser\u00e9lik vagy kieg\u00e9sz\u00edtik.<\/li>\n<li><strong>Koleszterin epek\u0151 felold\u00e1s<\/strong> \u2014 \u00e1tl\u00e1tsz\u00f3 k\u00f6vek (&lt; 15 mm) eset\u00e9n m\u0171k\u00f6d\u0151 epeh\u00f3lyagban, olyan betegekn\u00e9l, akik nem vagy nem akarnak cholecystectomi\u00e1t v\u00e9gezni. 8\u201310 mg\/kg\/nap 6\u201324 h\u00f3napig. A k\u00f6vek visszat\u00e9r\u00e9se a kezel\u00e9s befejez\u00e9se ut\u00e1n jelent\u0151s (\u2248 50% 5 \u00e9ven bel\u00fcl).<\/li>\n<li><strong>Primer sclerosing cholangitis (PSC)<\/strong> \u2014 jav\u00edtja a biok\u00e9miai \u00e9rt\u00e9keket; a mortalit\u00e1sra gyakorolt hat\u00e1s nem bizony\u00edtott. A magas adag (28\u201330 mg\/kg\/nap) rosszabb eredm\u00e9nyekkel j\u00e1r \u00e9s ellenjavallt.<\/li>\n<li><strong>Terhess\u00e9gi intrahepaticus cholestasis (ICP)<\/strong> \u2014 10\u201315 mg\/kg\/nap (vagy 500 mg naponta k\u00e9tszer); cs\u00f6kkenti az anyai viszket\u00e9st \u00e9s az epecukorszintet; cs\u00f6kkentheti a magzati sz\u00f6v\u0151dm\u00e9nyek kock\u00e1zat\u00e1t.<\/li>\n<li><strong>Nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g (NAFLD)<\/strong> \u2014 a biok\u00e9miai \u00e9rt\u00e9kek javulnak, de a magas szint\u0171 hisztol\u00f3giai el\u0151ny nem bizony\u00edtott; nem els\u0151 vonalbeli NAFLD kezel\u00e9s a jelenlegi ir\u00e1nyelvek szerint.<\/li>\n<li><strong>Cyst\u00e1s fibr\u00f3zis \u00e1ltal kiv\u00e1ltott m\u00e1jbetegs\u00e9g<\/strong> \u2014 haszn\u00e1latos gyermek- \u00e9s feln\u0151ttkori CF cholestasisban.<\/li>\n<\/ul>\n<h2>Adagol\u00e1s<\/h2>\n<table>\n<thead>\n<tr>\n<th>Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\n<th>Adag (mg\/kg\/nap)<\/th>\n<th>Szed\u00e9si rend<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>PBC<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 r\u00e9szadag \u00e9tkez\u00e9sekhez<\/td>\n<\/tr>\n<tr>\n<td>Koleszterin epek\u0151 felold\u00e1s<\/td>\n<td>8\u201310<\/td>\n<td>2 r\u00e9szadag (a legnagyobb adag lefekv\u00e9skor)<\/td>\n<\/tr>\n<tr>\n<td>PSC<\/td>\n<td>13\u201315 (ne haladja meg a 28 mg\/kg-ot)<\/td>\n<td>2\u20133 adagol\u00e1sra osztva<\/td>\n<\/tr>\n<tr>\n<td>ICP (terhess\u00e9g)<\/td>\n<td>10\u201315<\/td>\n<td>2 adagol\u00e1sra osztva<\/td>\n<\/tr>\n<tr>\n<td>NAFLD kieg\u00e9sz\u00edt\u0151 kezel\u00e9s<\/td>\n<td>13\u201315<\/td>\n<td>2\u20133 adagol\u00e1sra osztva<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Ker\u00fclend\u0151<\/h3>\n<ul>\n<li>Akut cholecystitis, cholangitis vagy epe\u00fati obstrukci\u00f3<\/li>\n<li>Meszes vagy pigment epek\u0151 (nem old\u00f3dik)<\/li>\n<li>Nem m\u0171k\u00f6d\u0151 epeh\u00f3lyag sz\u00e1j\u00fa cholecystogr\u00e1fi\u00e1n<\/li>\n<li>S\u00falyos m\u00e1jdekompenz\u00e1ci\u00f3 (Child-Pugh C) \u2013 konzult\u00e1ljon hepatol\u00f3gussal<\/li>\n<\/ul>\n<\/div>\n<h2>Mell\u00e9khat\u00e1sok<\/h2>\n<p>\u00c1ltal\u00e1ban nagyon j\u00f3l toler\u00e1lt. Leggyakoribb mell\u00e9khat\u00e1sok: enyhe hasmen\u00e9s (5\u201310%), hasi diszkomfort, h\u00e1nyinger, enyhe ki\u00fct\u00e9s. A viszket\u00e9s \u00e1tmenetileg s\u00falyosbodhat primer epe\u00fati m\u00e1jzsugor (PBC) eset\u00e9n a kezel\u00e9s els\u0151 heteiben, miel\u0151tt javulna. Ritk\u00e1n: epek\u0151-kalciumosod\u00e1s (r\u00e1di\u00f3op\u00e1k eltol\u00f3d\u00e1s) hossz\u00fa t\u00e1v\u00fa kezel\u00e9s sor\u00e1n.<\/p>\n<h2>Gy\u00f3gyszerk\u00f6lcs\u00f6nhat\u00e1sok<\/h2>\n<ul>\n<li><strong>Epesav-k\u00f6t\u0151 szerek (kolesztiramin, kolesezvel\u00e1m, kolestipol)<\/strong> \u2014 k\u00f6tik a UDCA-t a b\u00e9lben \u00e9s cs\u00f6kkentik a felsz\u00edv\u00f3d\u00e1s\u00e1t. Legal\u00e1bb 4\u20135 \u00f3r\u00e1val k\u00fcl\u00f6n id\u0151z\u00edts\u00e9k.<\/li>\n<li><strong>Alum\u00edniumot tartalmaz\u00f3 gyomorsavk\u00f6vet\u0151k<\/strong> \u2014 k\u00f6tik a UDCA-t. Legal\u00e1bb 2 \u00f3r\u00e1val k\u00fcl\u00f6n id\u0151z\u00edts\u00e9k.<\/li>\n<li><strong>\u00d6sztrog\u00e9nek, fogamz\u00e1sg\u00e1tl\u00f3 tablett\u00e1k, klofibr\u00e1t<\/strong> \u2014 n\u00f6velik az epe koleszterin tel\u00edtetts\u00e9g\u00e9t \u00e9s g\u00e1tolj\u00e1k az epek\u0151-old\u00f3 hat\u00e1st.<\/li>\n<li><strong>Ciprofloxacin, dapson<\/strong> \u2014 enyh\u00e9n m\u00f3dosul a felsz\u00edv\u00f3d\u00e1s; klinikailag jelent\u00e9ktelen.<\/li>\n<\/ul>\n<h2>Terhess\u00e9g \u00e9s szoptat\u00e1s<\/h2>\n<p>Rutinszer\u0171en off-label haszn\u00e1latos terhess\u00e9gi intrahepaticus cholestasisban, kiterjedt biztons\u00e1gi adatokkal. Szoptat\u00e1ssal egy\u00fctt haszn\u00e1lhat\u00f3 (nyomokban \u00fcr\u00fcl a tejbe; nincs jelentett csecsem\u0151k\u00e1r).<\/p>\n<h2>T\u00e1rol\u00e1s<\/h2>\n<p>25 \u00b0C alatt, sz\u00e1raz helyen, eredeti csomagol\u00e1sban t\u00e1roland\u00f3. A tablett\u00e1k sz\u00e1raz k\u00f6r\u00fclm\u00e9nyek k\u00f6z\u00f6tt a c\u00edmk\u00e9zett szavatoss\u00e1gi id\u0151n kereszt\u00fcl stabilak.<\/p>\n<h3>Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n<p>Az Udiliv egy WHO-GMP tan\u00fas\u00edtv\u00e1nnyal rendelkez\u0151 gy\u00e1rt\u00f3t\u00f3l sz\u00e1rmazik, teljes COA dokument\u00e1ci\u00f3val. Vil\u00e1gszerte sz\u00e1ll\u00edtunk egyszer\u0171, diszkr\u00e9t csomagol\u00e1sban, \u00e9s minden rendel\u00e9st fedez a <a href=\"\/hu\/medsbase-re-shipment-assurance-policy\/\">\u00dajrak\u00fcld\u00e9si Garancia<\/a>. A k\u00e1rty\u00e1s fizet\u00e9s sor\u00e1n megjelen\u0151 tranzakci\u00f3le\u00edr\u00f3 a fel\u00fcgyelt fizet\u00e9si feldolgoz\u00f3t mutatja (egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t), soha nem a \"MedsBase\" vagy b\u00e1rmilyen gy\u00f3gyszer neve.<\/p>\n<h2 id=\"faqs\">Gyakran Ism\u00e9telt K\u00e9rd\u00e9sek<\/h2>\n<h3>Mennyi id\u0151 alatt l\u00e1that\u00f3ak az eredm\u00e9nyek primer epe\u00fati m\u00e1jzsugorban?<\/h3>\n<p>Az alk\u00e1li foszfat\u00e1z szintje \u00e1ltal\u00e1ban 4\u20138 h\u00e9ten bel\u00fcl cs\u00f6kken, \u00e9s a 12 h\u00f3napos tendencia el\u0151rejelzi a hossz\u00fa t\u00e1v\u00fa eredm\u00e9nyt. A Toronto, Paris-1 \u00e9s Paris-2 krit\u00e9riumok szerint egy \u201cbiok\u00e9miai v\u00e1laszad\u00f3\u201d 1 \u00e9v ut\u00e1n ALP, AST \u00e9s bilirubin k\u00fcsz\u00f6b\u00e9rt\u00e9kek alapj\u00e1n defini\u00e1lhat\u00f3. A nem v\u00e1laszad\u00f3knak obeticholsav vagy fibr\u00e1t kieg\u00e9sz\u00edt\u00e9sr\u0151l kell hepatol\u00f3gussal konzult\u00e1lniuk.<\/p>\n<h3>Feloldhatja a UDCA b\u00e1rmilyen epek\u0151vet?<\/h3>\n<p>Csak koleszterin k\u00f6veket, csak ha \u00e1ttetsz\u0151ek a k\u00e9palkot\u00e1son, csak m\u0171k\u00f6d\u0151 epeh\u00f3lyagban, \u00e9s csak &lt; 15 mm eset\u00e9n. Kalcifik\u00e1lt, pigment vagy r\u00e9szben kalcifik\u00e1lt k\u00f6vek nem reag\u00e1lnak.<\/p>\n<h3>Why does my doctor want me on UDCA forever for PBC?<\/h3>\n<p>PBC is a chronic autoimmune cholangitis. UDCA changes the disease trajectory but does not cure it. Stopping UDCA is followed by biochemical relapse within weeks. Lifelong therapy at 13\u201315 mg\/kg\/day is standard.<\/p>\n<h3>Szedhetem terhess\u00e9g alatt?<\/h3>\n<p>Yes \u2014 UDCA is the standard treatment for intrahepatic cholestasis of pregnancy. It reduces maternal pruritus and bile acid levels.<\/p>\n<h3>Will UDCA cause weight loss or weight gain?<\/h3>\n<p>Neither, in most patients. Mild diarrhoea may cause minor early weight loss in a small fraction.<\/p>\n<h3>Does UDCA work for non-alcoholic fatty liver?<\/h3>\n<p>It improves biochemistry (ALT, AST). Whether it improves liver histology and outcomes is not established in large trials. Current NAFLD\/NASH guidelines do not recommend UDCA as routine therapy.<\/p>\n<h3>Can I drink alcohol on UDCA?<\/h3>\n<p>Most patients on UDCA have an underlying liver condition. Alcohol is best avoided altogether in PBC, PSC and significant hepatic disease.<\/p>\n<h3>What is the difference between UDCA and bile salts in supplements?<\/h3>\n<p>UDCA is a specific bile acid (ursodeoxycholic). Generic \u201cbile salt\u201d supplements are mixtures of natural bile acids without therapeutic dose standardisation. Only purified UDCA tablets are used clinically for PBC and gallstone dissolution.<\/p>\n<h3>How is UDCA monitored?<\/h3>\n<p>For PBC: ALP, ALT, AST, GGT, total bilirubin every 3 months for the first year, then 6-monthly. For gallstone dissolution: ultrasound at 6, 12, and 24 months to track stone size.<\/p>\n<h3>Can high-dose UDCA be harmful?<\/h3>\n<p>In primary sclerosing cholangitis, doses \u2265 28 mg\/kg\/day were associated with WORSE clinical outcomes (Lindor 2009 NEJM). Stick to 13\u201315 mg\/kg\/day in PSC and never escalate without specialist input.<\/p>\n<h2>Egy\u00e9b m\u00e1j- \u00e9s hepatol\u00f3giai term\u00e9kek<\/h2>\n<ul>\n<li><a href=\"\/hu\/ursodec\/\">Ursodec (UDCA 150 mg) \u2013 alacsonyabb er\u0151ss\u00e9g\u0171 UDCA, finomabb adagol\u00e1si lehet\u0151s\u00e9g<\/a><\/li>\n<li><a href=\"\/hu\/hepatitis-medication\/\">Minden m\u00e1j- \u00e9s hepatol\u00f3giai k\u00e9sz\u00edtm\u00e9ny<\/a><\/li>\n<li><a href=\"\/hu\/hepcinat\/\">Hepcinat (szofoszbuviros) \u2013 k\u00f6zvetlen hat\u00e1s\u00fa v\u00edrusellenes gy\u00f3gyszer kr\u00f3nikus HCV-hez<\/a><\/li>\n<li><a href=\"\/hu\/myhep-all\/\">MyHep (szofoszbuviros + velpatasvir) \u2013 pan-genot\u00edpusos HCV-specifikus gy\u00f3gyszer<\/a><\/li>\n<li><a href=\"\/hu\/celin\/\">Celin (C-vitamin) \u2013 antioxid\u00e1ns kieg\u00e9sz\u00edt\u0151<\/a><\/li>\n<li><a href=\"\/hu\/l-glutathione-250mg\/\">L-Glutathion (250 mg) \u2013 antioxid\u00e1ns a m\u00e1ji redox-t\u00e1mogat\u00e1shoz<\/a><\/li>\n<\/ul>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0 0 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;\">Orvosi felel\u0151ss\u00e9gi nyilatkozat<\/h3>\n<p style=\"margin:0;\">Ez az inform\u00e1ci\u00f3 kiz\u00e1r\u00f3lag oktat\u00e1si c\u00e9lokat szolg\u00e1l, \u00e9s nem helyettes\u00edti az orvosi tan\u00e1csot. Mindig konzult\u00e1ljon k\u00e9pzett eg\u00e9szs\u00e9g\u00fcgyi szakemberrel b\u00e1rmilyen gy\u00f3gyszer szed\u00e9s\u00e9nek megkezd\u00e9se, m\u00f3dos\u00edt\u00e1sa vagy le\u00e1ll\u00edt\u00e1sa el\u0151tt.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u2705 Feloldja az epek\u0151ket<br \/>\n\u2705 Enyh\u00edti az epepang\u00e1st<br \/>\n\u2705 M\u00e1jsejtek v\u00e9delme<br \/>\n\u2705 Cs\u00f6kkenti a m\u00e1jgyullad\u00e1st<br \/>\n\u2705 Jav\u00edtja a m\u00e1jm\u0171k\u00f6d\u00e9st<\/p>\n<p>Az Udiliv ursodeoxikolsavat tartalmaz.<\/p>","protected":false},"featured_media":61016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334],"product_tag":[4965,4728],"class_list":{"0":"post-61015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_tag-udiliv","10":"product_tag-ursodeoxycholic-acid","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product\/61015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/comments?post=61015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media\/61016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media?parent=61015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_brand?post=61015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat?post=61015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_tag?post=61015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}